S

Stoke Therapeutics
D

STOK

8.29000
USD
-0.45
(-5.15%)
مغلق
حجم التداول
37,425
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
439,096,239
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Stoke Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.